PHF8 and melanoma: In both the ICB clinical cohorts of melanoma treated with combined anti-PD-1 and anti-CTLA-441 and gastric cancer treated with anti-PD-142, responders showed significantly lower PHF8 expression levels than non-responders, suggesting that PHF8 expression was anti-correlated with ICB responses (Fig. 7i).